跳至主要内容
临床试验/NCT05901571
NCT05901571尚未招募不适用

Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): Study Design of a Randomized Controlled Trial

Shanghai 7th People's Hospital3 个研究点 分布在 1 个国家目标入组 216 人开始时间: 2026年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
216
试验地点
3
主要终点
HDRS-17 scale

研究概览

简要总结

We will be able to investigate in a sample of patients free of antidepressants whether acupuncture is more effective than placebo.

详细描述

This is a multicenter, randomized, controlled, 2 by 2 factorial clinical trial for Major depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Between 18 and 75 years of age with no gender-based restriction.
  • •Fulfilling the diagnostic criteria of DSM-5 for major depressive disorder.
  • •A Hamilton Rating Scale for Depression (HDRS-17) score ≥ 17
  • •Ability to read and understand Mandarin Chinese, at least nine years of education, and willingness to adhere to the study protocol.
  • •The absence of acupuncture treatment within at least 1 year.
  • •Willingness to participate in the trial and provide written informed consent for the clinical trial.

排除标准

  • •Lifetime or current neuropsychiatric conditions, such as bipolar disorder, schizophrenia, substance dependence or abuse, dementia, brain injury, epilepsy and so forth.
  • •High suicide risk or presenting with suicidal ideation (a score of more than 2 points on the Suicide question of the HDRS-17) at the time of entry.
  • •Medicated with antidepressant at the start of the trial or history of treatment failure to escitalopram.
  • •Pregnancy or breastfeeding.
  • •Subjects who have acute inflammation at the planned acupuncture site on the body or any other contraindication to acupuncture.
  • •Candidates afraid of needles in general and reluctant to receive acupuncture in particular
  • •Known or suspected clinically unstable systemic medical disorder (including cancer, organ failure, or severe diseases of the cardiovascular, severe hepatic or renal insufficiency).
  • •Previous participation in other acupuncture trials.

研究组 & 干预措施

sham-acupuncture/escitalopram

Active Comparator

sham-acupuncture protocol plus escitalopram

干预措施: sham-acupuncure (Other)

sham-acupuncture/escitalopram

Active Comparator

sham-acupuncture protocol plus escitalopram

干预措施: escitalopram (Other)

sham-acupuncture/placebo-pill

Sham Comparator

sham-acupuncture protocol plus escitalopram placebo

干预措施: escitalopram placebo (Other)

sham-acupuncture/placebo-pill

Sham Comparator

sham-acupuncture protocol plus escitalopram placebo

干预措施: sham-acupuncure (Other)

active acupuncture/placebo-pill

Active Comparator

acupuncture protocol plus escitalopram placebo

干预措施: acupuncture (Other)

active acupuncture/escitalopram

Experimental

acupuncture protocol plus escitalopram

干预措施: acupuncture (Other)

active acupuncture/placebo-pill

Active Comparator

acupuncture protocol plus escitalopram placebo

干预措施: escitalopram placebo (Other)

active acupuncture/escitalopram

Experimental

acupuncture protocol plus escitalopram

干预措施: escitalopram (Other)

结局指标

主要结局

HDRS-17 scale

时间窗: from baseline to 10 weeks

the change in the HDRS-17 score

次要结局

  • Beck depression inventory scale(from baseline to 10 weeks)
  • The CGI(Clinical Global Impression) scale(from baseline to 10 weeks)
  • The GAD-7(General Anxiety Disorder) scale(from baseline to 10 weeks)
  • The Mini-Mental State Examination (MMSE) scale(from baseline to 10 weeks)

研究者

发起方
Shanghai 7th People's Hospital
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验